年龄对瑞马唑仑诱导至意识消失所需剂量的影响

注册号:

Registration number:

ChiCTR2300069582 

最近更新日期:

Date of Last Refreshed on:

2023-06-15 20:13:14 

注册时间:

Date of Registration:

2023-03-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

年龄对瑞马唑仑诱导至意识消失所需剂量的影响

Public title:

Effect of Age on Remimazolam Requirement for Loss of Consciousness in Elderly Surgical Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

年龄对瑞马唑仑诱导至意识消失所需剂量的影响

Scientific title:

Effect of Age on Remimazolam Requirement for Loss of Consciousness in Elderly Surgical Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

宋金超 

研究负责人:

宋金超 

Applicant:

Jinchao Song 

Study leader:

Jinchao Song 

申请注册联系人电话:

Applicant telephone:

+86 131 6700 0520

研究负责人电话:

Study leader's
telephone:

+86 131 6700 0520

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sjch2013@163.com

研究负责人电子邮件:

Study leader's E-mail:

sjch2013@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市市光路999号

研究负责人通讯地址:

上海市市光路999号

Applicant address:

999 Shiguang Road, Shanghai, China

Study leader's address:

999 Shiguang Road, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

200438

研究负责人邮政编码:

Study leader's postcode:

200438

申请人所在单位:

上海市杨浦区市东医院

Applicant's institution:

Shidong Hospital of Shanghai

研究负责人所在单位:

上海市杨浦区市东医院

Affiliation of the Leader:

Shidong Hospital of Shanghai

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-039-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市杨浦区市东医院 临床研究伦理委员会

Name of the ethic committee:

the Committee on Ethics of Biomedicine Research, Shanghai Yangpu District Shidong Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-09-01 00:00:00

伦理委员会联系人:

陈香香

Contact Name of the ethic committee:

Xiangxiang Chen

伦理委员会联系地址:

上海市光路999号

Contact Address of the ethic committee:

999 Shiguang Road, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 25066666

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市市东医院

Primary sponsor:

Department of Anesthesiology, Shanghai Yangpu District Shidong Hospital

研究实施负责(组长)单位地址:

上海市市光路999

Primary sponsor's address:

999 Shiguang Road, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市市东医院

具体地址:

市光路999号

Institution
hospital:

Shanghai Yangpu District Shidong Hospital

Address:

999 Shiguang Road, Shanghai, China

经费或物资来源:

国家自然科学基金 (No.81371511)

Source(s) of funding:

National Natural Science Foundation of China (No.81371511)

研究疾病:

药效动力学  

Target disease:

Pharmacodynamics

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

阐明老年患者使用瑞马唑仑的药效动力学;明确老年患者在使用瑞马唑仑时循环动力学的改变。从而更加合理地指导临床用药。  

Objectives of Study:

To investigate the effect of age on remimazolam requirement for LOC in elderly surgical patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

有严重心、肝、肺、肾功能不全的患者。

Exclusion criteria:

1. Patients were allergic to the planned medication at the time of enrolment; 2. Who were known to have severe cardiac and cerebral vascular diseases, central nervous system diseases, hematologic and metabolic diseases, increased intracranial pressure and hepatic or renal abnormality. 3. Patients who had history of alcohol or drug abuse and usage of analgesic or neuromodulating medications.

研究实施时间:

Study execute time:

From 2023-04-01 00:00:00 To 2023-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2023-08-31 00:00:00

干预措施:

Interventions:

组别:

成人组

样本量:

60

Group:

group A

Sample size:

干预措施:

瑞马唑仑

干预措施代码:

Intervention:

remimazolam

Intervention code:

组别:

老年组

样本量:

60

Group:

group B

Sample size:

干预措施:

瑞马唑仑

干预措施代码:

Intervention:

remimazolam

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市市东医院 

单位级别:

三级 

Institution
hospital:

Shanghai Shidong Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

诱导至睫毛反射消失的静脉麻醉药使用量

指标类型:

主要指标

Outcome:

Amount of intravenous anesthetic used to induce disappearance of eyelash reflex

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 95 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究分组由患者年龄决定分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

120 patients scheduled for general surgery under general anesthesia were included and divided into 2 groups, Group A (60 patients, 18-64 years), Group B (60 patients, >= 65 years), according to age.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-21 11:30:50